News on Medial

Related News

Asaya raises $3 Mn in pre-Series A round led by RPSG Capital

EntrackrEntrackr · 6m ago
Asaya raises $3 Mn in pre-Series A round led by RPSG Capital
Medial

Asaya, a research-backed skincare brand focused on hyperpigmentation, has raised Rs 28 crore (around $3 million) in a pre-Series A round led by RPSG Capital. Other investors include Suyash Saraf and Anisha Agarwal Saraf, co-founders of Dot & Key, alongside existing backers OTP Ventures and Huddle Ventures. The proceeds will be used to set up a state-of-the-art innovation center, accelerate product development, and expand distribution. Founded by Neeraj Biyani, Anupam Sinha and Ritu Malhotra, Asaya’s current product line includes serums, creams, face masks, and treatments for hyperpigmentation, uneven skin tone, and related concerns. The firm follows a direct-to-consumer (D2C) model, selling via its own online channels, quick-commerce platforms, and select offline retail. This approach allows it to control pricing, maintain transparency, and bring research-driven solutions directly to consumers. Asaya claims to have grown 400% year-on-year, driven by its proprietary patented molecule MelaMe™, which delivers clinically proven results in 14 days and has consistently outperformed global beauty brands in tests on Indian skin types. Asaya plans to launch six new products in the next 12 months, including a line featuring another patented molecule targeting a major Indian skin concern after 1.5 years of research. Asaya competes with both multinational giants like L’Oréal, P&G, and Unilever and homegrown digital-first brands such as Mamaearth, Minimalist, and Dot & Key.

Skincare brand Be Clinical raises seed round led by V3 Ventures

EntrackrEntrackr · 2m ago
Skincare brand Be Clinical raises seed round led by V3 Ventures
Medial

Skincare brand Be Clinical raises seed round led by V3 Ventures Skincare brand Be Clinical has raised Rs 6 crore in a seed funding round led by V3 Ventures, with participation from Titan Capital, founded by Kunal Bahl and Rohit Bansal, who have doubled down on their commitment to the brand. The Mumbai-based brand had previously mopped up Rs 2 crore in the same funding round led by Titan Capital, along with participation from P-TAL founder Aditya Agarwal. The proceeds will be used for research and development to strengthen in-house formulation capabilities, conduct clinical testing, and develop targeted solutions for ageing concerns across the face, body, and scalp, Be Clinical said in a press release. Launched in May last year by Hemangi Dhir, Be Clinical is an evidence-led skincare brand offering clinically tried solutions for ageing skin, developed specifically for Indian skin and conditions. Backed by in-house research and dermatologically active ingredients, the brand addresses ageing concerns with a strong focus on transparency, education, and measurable results. Be Clinical aims to address a gap in the Indian skincare market such as the lack of science-led, transparent, and clinically validated solutions designed specifically for Indian skin and environmental conditions. The brand says that it differentiates itself through in-vivo tested, clinically validated formulations, supported by end-to-end in-house research and manufacturing and responsible formulation. Since its inception, Be Clinical claims that it has demonstrated strong early traction in a short period and served over 25,000 customers, reflecting rapid adoption and growing consumer trust in its clinically driven, India-specific skincare solutions. The company plans to expand its manufacturing facility by adding advanced machinery to improve production capacity, consistency, and quality control. The brand aspires to upgrade packaging with functional, protective, and premium formats that preserve ingredient efficacy while reinforcing the brand’s clinical-grade positioning. It competes with other notable players such as Olay, Neutrogena, Clinique, and Dr. Sheth in the anti-ageing category.

Download the medial app to read full posts, comements and news.